文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

法布雷病峰值氧耗变化与心肌病严重程度的相关性

Changes in peak oxygen consumption in Fabry disease and associations with cardiomyopathy severity.
PubMed 文献 · Heart · 2025-02-12

这项回顾性观察研究纳入42例在英国国家转诊中心接受心肺运动试验的法布雷病成人患者,发现峰值氧摄取量(V̇O2peak)随心肌病分期显著下降(p=0.010),且在无心肌病表型的I期患者中已较年龄和性别正常值低23%(p=0.006),而规范化FEV1无相应显著变化(p=0.683)。

要点

  • 法布雷病患者在心肌病I期即出现V̇O2peak显著受损,较正常值低23%。
  • V̇O2peak随心肌病分期进展显著下降,IV期均值降至21.2±6.1 mL/kg/min。
  • 规范化FEV1未随心肌病分期显著变化,提示运动不耐受非呼吸功能受损所致。

核心结论

  • 法布雷病患者存在显著有氧能力受损,即使无心肌病表型亦如此。
  • 运动不耐受可能源于早期心脏鞘脂蓄积及随后的心房和心室功能障碍,并随心肌病进展而加重。
  • V̇O2peak有望作为法布雷病特异性治疗反应的治疗标志物。

研究设计与样本

  • 回顾性观察研究,纳入2011年9月至2023年9月在英国国家转诊中心接受心肺运动试验(CPEX)的法布雷病成人患者42例。
  • 中位年龄54岁,62%为男性,患者约均匀分布于四个心肌病分期。
  • 心肌病分期由两名法布雷病专家基于同期影像学和生化结果按4分制分类。
  • 主要结局指标为峰值氧摄取量(V̇O2peak),并以FEV1量化呼吸功能受损,另计算基于已发表年龄和性别正常范围的年龄/性别规范化值。

主要发现

  • I期患者平均(±SD)V̇O2peak为28.7±7.7 mL/kg/min,较年龄和性别规范化值(预期均值37.3±3.2 mL/kg/min)显著低23%(p=0.006)。
  • V̇O2peak随心肌病分期显著下降(p=0.010),IV期均值降至21.2±6.1 mL/kg/min。
  • 规范化FEV1未随心肌病分期显示相应显著变化(p=0.683)。
  • 左心房整体纵向应变受损及炎症生化标志物与V̇O2peak受损相关。

临床怎么用

  • 对法布雷病患者应关注V̇O2peak评估有氧能力,即使无心肌病表型亦可能存在显著受损。
  • V̇O2peak可考虑作为法布雷病特异性治疗反应的治疗标志物。
  • 运动不耐受的评估不应仅归因于呼吸功能受损,需关注早期心脏受累。

局限性

  • 回顾性观察设计,样本量较小(42例)。
  • 单中心国家转诊中心研究,结果外推需谨慎。
  • 心肌病分期基于同期影像学和生化结果由专家分类,可能存在主观性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fabry disease (FD) causes multiorgan sphingolipid accumulation, with cardiac involvement responsible for the largest burden of morbidity and mortality. Exercise intolerance in FD is prevalent, yet the mechanisms of this are poorly understood. The aim of this study was to assess exercise intolerance in FD and identify whether this correlates with the phase of cardiomyopathy. METHODS: This was a retrospective observational study of adults with FD undergoing cardiopulmonary exercise testing (CPEX) between September 2011 and September 2023 at a national referral centre in the UK. The primary outcome measure was peak oxygen uptake (V̇O2peak), with forced expiratory volume in 1 s (FEV1) used to quantify respiratory impairment. Age-normalised/sex-normalised values were additionally calculated, based on published normal ranges for subgroups of age and sex. The cardiomyopathy phase was classified on a 4-point scale by two FD experts using contemporaneous imaging and biochemistry results. RESULTS: CPEX was completed by 42 patients, with a median age of 54 years and of whom 62% were male. Patients were approximately equally distributed across the four cardiomyopathy phases. At phase I, the mean (±SD) V̇O2peak was 28.7±7.7 mL/kg/min, which represented a significant underperformance of 23%, relative to age-normalised and sex-normalised values (expected mean: 37.3±3.2 mL/kg/min, p=0.006). V̇O2peak declined significantly across the cardiomyopathy phases (p=0.010), reaching a mean of 21.2±6.1 mL/kg/min at phase IV. Normalised FEV1 was not found to show a corresponding significant change with cardiomyopathy phase (p=0.683). Impaired left atrial global longitudinal strain as well as biochemical markers of inflammation were associated with impaired V̇O2peak. CONCLUSIONS: This study identifies significantly impaired aerobic capacity in FD, even in those without phenotypic cardiomyopathy. No corresponding changes in respiratory impairment were observed, suggesting that exercise intolerance may be due to early cardiac sphingolipid accumulation and subsequent atrial and ventricular dysfunction, which increases as cardiomyopathy progresses. As such, peak V̇O2peak holds promise as a therapeutic marker of response to FD-specific therapy.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Roy A, Thompson SE, Hodson J, et al. Changes in peak oxygen consumption in Fabry disease and associations with cardiomyopathy severity. Heart. 2025. PMID: 39586663. doi:10.1136/heartjnl-2024-324553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。